Four pharmaceutical companies involved in centralized procurement have been listed as violating the rules.

MetaMuskRat · 2026-04-08T09:03:34+00:00

People's Financial News, April 8 — Recently, the National Organization for Drug Joint Procurement Office announced the cancellation of Guangzhou Hehe Medical Co., Ltd.'s qualification for the selection of Mesobamol Injection, and also listed the company and its entrusted manufacturer, Chengdu Tiantaishan Pharmaceutical Co., Ltd., on the violation list; the qualification for the selection of Beijing Fukang Rensheng Biological Pharmaceutical Technology Co., Ltd.'s Dopamine Hydrochloride Injection and Xidelong's Dapagliflozin Tablets has been canceled, and both companies have been added to the violation list. (Xinhua News Agency)

MetaMuskRat

2026-04-08 09:03:34

People’s Finance and News, April 8—Recently, the National Organization for Drug Centralized Procurement Office issued an announcement to cancel the winning qualification of Mesobamone injection by Guangzhou Hehe Pharmaceutical Co., Ltd., and, at the same time, add the company and its entrusted manufacturing company, Chengdu Tian Tianshan Pharmaceutical Co., Ltd., to the list of violators. In addition, it canceled the winning qualifications of Dopamine Hydrochloride Injection by Beijing Fukanren Biopharmaceutical Technology Co., Ltd. and Dapagliflozin Tablets by the company Shide Long, and, at the same time, added the two companies to the list of violators. (Xinhua News Agency)

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.